Dobbin, Zachary C <br/><br/>
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.  [electronic resource] 

 -  Oncotarget  Sep 2014 
 - 8750-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.2373  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Biomarkers, Tumor--genetics<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Gene Expression Profiling<br/>Gene Expression Regulation, Neoplastic<br/>Gene Regulatory Networks<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Immunohistochemistry<br/>Mice, SCID<br/>Middle Aged<br/>Neoplasm Transplantation<br/>Neoplastic Stem Cells--drug effects<br/>Ovarian Neoplasms--drug therapy<br/>Patient Selection<br/>Polymerase Chain Reaction<br/>Precision Medicine<br/>Predictive Value of Tests<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays